<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001606831</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001607678</issuerCik>
      <issuerName>Viking Therapeutics, Inc.</issuerName>
      <secFileNumber>001-37355</secFileNumber>
      <issuerAddress>
        <com:street1>9920 PACIFIC HEIGHTS BLVD, SUITE 350</com:street1>
        <com:city>SAN DIEGO</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>92121</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>858-704-4660</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>MACARTNEY LAWSON</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>common</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Oppenheimer &amp; Co Inc</name>
        <address>
          <com:street1>85 Broad Street</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10004</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>20785</noOfUnitsSold>
      <aggregateMarketValue>415720.00</aggregateMarketValue>
      <noOfUnitsOutstanding>78418529</noOfUnitsOutstanding>
      <approxSaleDate>04/17/2023</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>common</securitiesClassTitle>
      <acquiredDate>04/28/2015</acquiredDate>
      <natureOfAcquisitionTransaction>NQ Grant</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>20786</amountOfSecuritiesAcquired>
      <paymentDate>04/17/2023</paymentDate>
      <natureOfPayment>N/A</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>POA on File</remarks>
    <noticeSignature>
      <noticeDate>04/17/2023</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>02/16/2023</planAdoptionDate>
      </planAdoptionDates>
      <signature>Lawson Macartney</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
[{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2855}]
144
0001606831
XXXXXXXX
LIVE
0001607678
Viking Therapeutics, Inc.
001-37355
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
858-704-4660
MACARTNEY LAWSON
Officer
common
Oppenheimer & Co Inc
85 Broad Street
New York
NY
10004
20785
415720.00
78418529
04/17/2023
NASDAQ
common
04/28/2015
NQ Grant
Issuer
N
20786
04/17/2023
N/A
Y
POA on File
04/17/2023
02/16/2023
Lawson Macartney